IGF2BP1 and breast carcinoma: The prognostic overexpression of IGF2BP1 has been reported in over 16 cancers, whereas the overexpression of IGF2BP1 in colon (Hamilton et al., 2015) and breast cancer (Wang, et al., 2016) relative to normal tissues remains controversial.